Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENOV vs MYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENOV Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

ENOV Overall Winner 6-Pillar Tally: ENOV 5 – 1 MYO Matrix Metrics: ENOV 8 – 2 MYO

As of Nov 20, 2026, Enovis Corporation (ENOV) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENOV carries a Unified Composite Score of 30.0/100 (SELL) at $25.47 (7.3x Forward P/E, 4.0% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin).

  • Composite vs. Pillar Nuance: While MYO currently prints a higher short-term Unified Composite Score (40.1/100 SELL vs. ENOV 30.0/100 SELL), ENOV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (4.0% vs. -21.8% operating margin) and revenue trajectory (+1.8% vs. +22.2% YoY).
  • Defensive Composite Rating Caution: Although ENOV compares more favorably head-to-head, both ENOV (30.0/100 SELL) and MYO (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ENOV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENOV vs MYO
ENOV NYSE Head-to-Head Winner
Enovis Corporation
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$25.47
-2.9% 1D
Market Cap $1.5B
TTM Revenue $2.31B
Forward P/E 7.3x
Beta / 30D Vol 0.75β · 101% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 15.0 Fund 28.0 Flow 50.0 Mom 21.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.2% over 20 days), RSI 54
RSI-14: 54.3 · SMA20: $25.18 · SMA50: $21.30
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (ENOV 5 – 1 MYO)

Columns: Metric · ENOV · MYO
1. Valuation Multiples ENOV
Forward P/E 7.3x N/M
Trailing P/E 7.5x N/M
PEG Ratio 1.90x N/M
EV / Revenue 0.7x 0.9x
2. Growth & Scale ENOV
Revenue Growth (YoY) +1.8% +22.2%
Earnings Growth (YoY) +153.1% +0.0%
TTM Revenue (USD) $2.31B $46M
Market Cap $1.5B $33.7M
3. Profitability & Quality ENOV
Gross Margin 61.3% 70.1%
Operating Margin 4.0% -21.8%
Net Profit Margin -22.9% -33.1%
Return on Equity (ROE) -29.9% -173.5%
4. Balance Sheet & Cash Flow ENOV
Cash Generation (TTM) $387M EBITDA -$9.1M
Cash Flow Margin 16.8% EBITDA Mgn -20.0%
Net Cash / Leverage $25.88 Book/Sh · -29.9% ROE $8.9M Net Debt (3.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 65.6% (43rd %ile) 266.0% (81st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ENOV
OpEx & R&D Intensity 57.3% of Rev ($1.32B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENOV (8) vs MYO (2)
Institutional Metric ENOV MYO Criterion Row Edge
Market Capitalization
Scale
$1.5B $33.7M Larger Scale ENOV
Trailing P/E Ratio
Valuation
7.5x N/M Lower Multiple ENOV
Forward P/E Ratio
Valuation
7.3x N/M Lower Multiple ENOV
Revenue Growth (YoY)
Growth
+1.8% +22.2% Higher Growth MYO
Operating Margin (TTM)
Profitability
4.0% -21.8% Higher Margin ENOV
Net Profit Margin
Profitability
-22.9% -33.1% Higher Margin ENOV
Return on Equity (ROE)
Capital Efficiency
-29.9% -173.5% Higher ROE ENOV
52-Week Range Position
Momentum
59% ($17–$32) 16% ($1–$2) Stronger Trend ENOV
Beta / 30D Volatility
Risk Regime
0.75β · 101% Vol 2.22β · 107% Vol Lower Realized Risk ENOV
Unified Institutional Score
Composite Signal
30.0 / 100 (SELL) 40.1 / 100 (SELL) Higher Composite MYO
Trailing 12M Revenue (USD)
Operating Scale
$2.31B $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.3% 70.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.90x PEG · 0.7x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$387M EBITDA ($25.88 Book/Sh · -29.9% ROE) -$9.1M ($8.9M Net Debt (3.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENOV +51.49 pp
ENOV: +17.97% · MYO: -33.52%
3M Horizon ENOV +42.68 pp
ENOV: +1.03% · MYO: -41.65%
6M Horizon ENOV +27.31 pp
ENOV: +5.29% · MYO: -22.02%
1Y Horizon MYO +18.56 pp
ENOV: -6.26% · MYO: +12.3%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENOV vs MYO. Trailing 12-month operating profitability (ENOV 4.0% vs MYO -21.8%) and valuation multiples (ENOV 7.3x vs MYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ENOV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.31B
Gross Margin61.3%
Op. Margin4.0%
ROE / Fwd P/E-29.9% · 7.3x
MYO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$46M
Gross Margin70.1%
Op. Margin-21.8%
ROE / Fwd P/E-173.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.6%
IV Percentile 43rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENOV Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.5B market capitalization and 4.0% operating margin.
OpEx & R&D Reinvestment 57.3% of Rev ($1.32B)
90D Engineering Disclosures 0 Published
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENOV vs MYO Key Questions & Quantitative Answers

As of Nov 20, 2026, Enovis Corporation (ENOV) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENOV carries a Unified Composite Score of 30.0/100 (SELL) at $25.47 (7.3x Forward P/E, 4.0% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin). Composite vs. Pillar Nuance: While MYO currently prints a higher short-term Unified Composite Score (40.1/100 SELL vs. ENOV 30.0/100 SELL), ENOV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (4.0% vs. -21.8% operating margin) and revenue trajectory (+1.8% vs. +22.2% YoY). Defensive Composite Rating Caution: Although ENOV compares more favorably head-to-head, both ENOV (30.0/100 SELL) and MYO (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ENOV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ENOV leads the Growth & Scale pillar: ENOV posts +1.8% YoY revenue growth and +153.1% YoY earnings growth on $2.31B TTM revenue (61.3% gross margin, 4.0% operating margin), compared with MYO at +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin). On trailing 12-month operating scale, ENOV generates $2.31B in USD-normalized revenue versus $46M for MYO. In operating R&D and SG&A reinvestment, ENOV deploys 57.3% of Rev ($1.32B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MYO.

ENOV screens cheaper on headline valuation multiples. ENOV trades at 7.3x Forward P/E, 7.5x Trailing P/E, 1.90x PEG, and 0.7x EV/Revenue (16.8% EBITDA margin), whereas MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENOV (-29.9% ROE) versus MYO (-173.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ENOV carries 65.6% implied volatility (43rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.75β · 101% Vol realized risk). By comparison, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.